Agape ATP Corp. Signs Material Definitive Agreement

Ticker: ATPC · Form: 8-K · Filed: Nov 29, 2024 · CIK: 1713210

Agape Atp Corp 8-K Filing Summary
FieldDetail
CompanyAgape Atp Corp (ATPC)
Form Type8-K
Filed DateNov 29, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: material-agreement

TL;DR

Agape ATP Corp. signed a big deal, details TBD.

AI Summary

Agape ATP Corp. entered into a material definitive agreement on November 29, 2024. The filing does not disclose the specific nature or terms of this agreement, only that it is a significant event for the company.

Why It Matters

This filing indicates a significant new development for Agape ATP Corp., potentially impacting its business operations and future strategy.

Risk Assessment

Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty regarding its implications for the company.

Key Players & Entities

  • Agape ATP Corp. (company) — Registrant
  • November 29, 2024 (date) — Date of Report

FAQ

What is the nature of the material definitive agreement entered into by Agape ATP Corp.?

The filing does not specify the details of the material definitive agreement.

When did Agape ATP Corp. enter into this material definitive agreement?

Agape ATP Corp. entered into the material definitive agreement on November 29, 2024.

What is the exact address of Agape ATP Corp.'s principal executive offices?

The address is 1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, Kuala Lumpur, Malaysia 58100.

What is Agape ATP Corp.'s telephone number?

The telephone number is +(60) 192230099.

What is the Commission File Number for Agape ATP Corp.?

The Commission File Number is 001-41835.

Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-29 09:00:53

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share ATPC NASDAQ Capital Mark

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 29, 2024 AGAPE ATP CORPORATION (Exact name of registrant as specified in its charter) Nevada 001-41835 36-4838886 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 1705 – 1708, Level 17, Tower 2, Faber Towers , Jalan Desa Bahagia , Taman Desa , Kuala Lumpur , Malaysia 58100 (Address of principal executive offices) (Zip Code) +(60) 192230099 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share ATPC NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into a Material Definitive Agreement On November 25, 2024, Agape ATP Corporation (the "Company") entered into three Memorandums of Understanding ("MOUs") with three health institutions in Indonesia, which include Dr. Sardjito General Hospital in Yogyakarta, Dr. H. A. Rotinsulu Lung Hospital in Bandung, and Dr. M. Goenawan Partowidigdo Respiratory Hospital in Bogor (collectively referred as the "Healthcare Institutions"), pursuant to which the Company and the Healthcare Institutions will collaborate on enhancing research capabilities, fostering medical innovations, and conducting clinical studies on the Company's existing health products. On November 29, 2024, the Company issued a press release (the "Press Release") announcing the MOUs. The Press Release and a copy of each MOU is furnished as Exhibit 99.1, 99.2, 99.3 and 99.4, respectively to this Current Report on Form 8-K and incorporated herein by reference. Exhibit Index Exhibit No. Description 99.1 Press Release, dated November 29, 2024 99.2 Memorandum of Understanding between Company and Dr. Sardjito General Hospital 99.3 Memorandum of Understanding between Company and Dr. H. A. Rotinsulu Lung Hospital 99.4 Memorandum of Understanding between Company and Dr. M. Goenawan Partowidigdo Respiratory Hospital 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGAPE ATP CORPORATION Date: November 29, 2024 By: /s/ How Kok Choong Name: How Kok Choong Title: Chief Executive Officer, President, Director, Secretary and Treasurer (Principal Executive Officer) 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.